Peripheral Arterial Disease Therapy using Angiogenesis in PLX-PAD cells

Peripheral Arterial Disease (PAD)

    Symptom vary from muscle pain when walking or using affected muscles
     (Intermittent Claudication, IC) to rest pain (Critical Limb Ischemia, CLI)
    Leading to chronic severe reduction in quality of life
    If untreated, tissue necrosis caused by lack of blood flow in blocked
     blood vessel
    Narrowed and blocked blood vessel mainly due to hardening of arteries

Limitation of Current Treatment

No regeneration in damaged blood vessels caused by lack of blood flow

CHA Biotech’s PLX-PAD

    Placenta-derived cell therapy product which has functions of secreting EGF
     (Epidermal Growth Factor) and VEGF (Vascular Endothelial Growth Factor)
    Korean market exclusivity acquired via strategic partnership with Pluristem
     Therapeutics in Israel (2013)

Cerebral Infarction Therapy using eCASs Program

Stroke

    Disease causing brain necrosis due to disturbance in blood vessel
      supplying blood to brain
    Associated with high mortality rate or survival with severe neurological
      deficits

CHA Biotech’s CB-AC-01

    Mesenchymal stem cell therapy derived from umbilical cord tissue
    Stored frozen and injectable immediately since no cultivation period require
    Co-development with CHA University and Bundang CHA Medical Center

Demonstrated robust safety profile for ‘Cordstem-ST’ via systemic administration Signals of efficacy seen
with statistical significance at week 24 during review time period

Alzheimer’s Disease Therapy using ePACs Program

Alzheimer’s Disease (AD)

    No definitive cause and mechanism of AD found
    Associated with severe memory problems and other intellectual disabilities
     to varying degrees, ultimately leading to death

Limitation of Current Treatment

No definite results identified to prevent or delay onset of AD
from 2 FDA-approved drugs

CHA Biotech’s CB-AC-02

    Mesenchymal stem cell therapy derived from umbilical tissue
    Stored frozen and injectable immediately since no cultivation period required
    Co-development with CHA University and Bundang CHA Medical Center

Research & Development

Research & DevelopmentR&D Pipeline

Peripheral Arterial Disease Therapy using Angiogenesis in PLX-PAD cells

No regeneration in damaged blood vessels caused by lack of blood flow

Placenta-derived cell therapy product which has functions of secreting EGF
     (Epidermal Growth Factor) and VEGF (Vascular Endothelial Growth Factor)
    Korean market exclusivity acquired via strategic partnership with Pluristem
     Therapeutics in Israel (2013)

Cerebral Infarction Therapy using eCASs Program

Disease causing brain necrosis due to disturbance in blood vessel
      supplying blood to brain
    Associated with high mortality rate or survival with severe neurological
      deficits

Mesenchymal stem cell therapy derived from umbilical cord tissue
    Stored frozen and injectable immediately since no cultivation period require
    Co-development with CHA University and Bundang CHA Medical Center

Alzheimer’s Disease Therapy using ePACs Program

No definitive cause and mechanism of AD found
    Associated with severe memory problems and other intellectual disabilities
     to varying degrees, ultimately leading to death

No definite results identified to prevent or delay onset of AD
from 2 FDA-approved drugs

Mesenchymal stem cell therapy derived from umbilical tissue
    Stored frozen and injectable immediately since no cultivation period required
    Co-development with CHA University and Bundang CHA Medical Center

Research & Development

Research & DevelopmentR&D Pipeline

Peripheral Arterial Disease Therapy using Angiogenesis in PLX-PAD cells

No regeneration in damaged blood vessels caused by lack of blood flow

Placenta-derived cell therapy product which has functions of secreting EGF (Epidermal Growth Factor) and VEGF (Vascular Endothelial Growth Factor) Korean market exclusivity acquired via strategic partnership with Pluristem Therapeutics in Israel (2013)

Cerebral Infarction Therapy using eCASs Program

Disease causing brain necrosis due to disturbance in blood vessel supplying blood to brain Associated with high mortality rate or survival with severe neurological deficits

Mesenchymal stem cell therapy derived from umbilical cord tissue Stored frozen and injectable immediately since no cultivation period require Co-development with CHA University and Bundang CHA Medical Center

Alzheimer’s Disease Therapy using ePACs Program

No definitive cause and mechanism of AD found Associated with severe memory problems and other intellectual disabilities to varying degrees, ultimately leading to death

No definite results identified to prevent or delay onset of AD from 2 FDA-approved drugs

Mesenchymal stem cell therapy derived from umbilical tissue Stored frozen and injectable immediately since no cultivation period required Co-development with CHA University and Bundang CHA Medical Center

Placenta-derived cell therapy product which has functions of secreting EGF
(Epidermal Growth Factor) and VEGF (Vascular Endothelial Growth Factor)
Korean market exclusivity acquired via strategic partnership with Pluristem
Therapeutics in Israel (2013)

Disease causing brain necrosis due to disturbance in blood vessel
supplying blood to brain
Associated with high mortality rate or survival with severe neurological
deficits

Mesenchymal stem cell therapy derived from umbilical cord tissue
Stored frozen and injectable immediately since no cultivation period require
Co-development with CHA University and Bundang CHA Medical Center

No definitive cause and mechanism of AD found
Associated with severe memory problems and other intellectual disabilities
to varying degrees, ultimately leading to death

No definite results identified to prevent or delay onset of AD
from 2 FDA-approved drugs

Mesenchymal stem cell therapy derived from umbilical tissue
Stored frozen and injectable immediately since no cultivation period required
Co-development with CHA University and Bundang CHA Medical Center